Table 2 Laboratory findings in postmenopausal women with rheumatoid arthritis who were given hormone replacement therapy and the control group
HRT | Controls | |||||
|---|---|---|---|---|---|---|
Laboratory test | Baseline | 12 months | 24 months | Baseline | 12 months | 24 months |
Serum TNF-α (pg/ml) | 4.1 ± 0.4 (32) | 3.8 ± 0.4 (30) | 3.6 ± 0.4 (32) | 4.4 ± 0.5 (44) | 4.1 ± 0.3 (43) | 4.2 ± 0.4 (44) |
Serum IL-1Ra (pg/ml) | 501 ± 49 (35) | 678 ± 82 (32)†† | 558 ± 85 (35) | 494 ± 77 (45) | 596 ± 104 (45)† | 606 ± 128 (45) |
Serum IL-6 (pg/ml) | 25.7 ± 6.3 (35) | 25.1 ± 8.3 (32) | 23.1 ± 5.2 (35) | 23.2 ± 4.3 (45) | 27.1 ± 4.5 (45) | 25.6 ± 5.4 (45) |
Serum sIL-6R (pg/ml) | 851 ± 46 (34) | 801 ± 41 (31)‡ | 790 ± 36 (34)†,‡ | 771 ± 31 (45) | 794 ± 35 (45) | 804 ± 34 (45) |
Serum OPG (pg/ml) | 104 ± 19 (30) | 133 ± 29 (28)‡ | 112 ± 19 (30) | 114 ± 14 (43) | 109 ± 13 (43) | 120 ± 13 (43) |
Serum IGF-1 (ng/ml) | 80.3 ± 4.9 (29) | 81.0 ± 4.0 (24) | 92.6 ± 4.6 (29)‡ | 78.6 ± 5.3 (40) | 78.3 ± 5.0 (40) | 77.7 ± 3.9 (40) |
ESR (mm) | 32.5 ± 3.2 (35) | 29.0 ± 3.2 (35) | 24.3 ± 2.2 (35)††,‡ | 27.3 ± 2.3 (43) | 26.6 ± 2.9 (41) | 26.7 ± 2.7 (43) |
Serum estradiol (pmol/l) | 44.4 ± 8.6 (27) | 176.7± 31.4 (22)†††,‡‡‡ | 160.9 ± 18.7 (27)†††,‡‡‡ | 38.0 ± 4.4 (36) | 39,0 ± 5,9 (36) | 38,9 ± 6,6 (36) |